Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload

Department of Pathology, UCLA, Los Angeles, California, USA.
The Journal of clinical investigation (Impact Factor: 13.22). 11/2011; 121(12):4880-8. DOI: 10.1172/JCI57693
Source: PubMed


Iron overload is the hallmark of hereditary hemochromatosis and a complication of iron-loading anemias such as β-thalassemia. Treatment can be burdensome and have significant side effects, and new therapeutic options are needed. Iron overload in hereditary hemochromatosis and β-thalassemia intermedia is caused by hepcidin deficiency. Although transgenic hepcidin replacement in mouse models of these diseases prevents iron overload or decreases its potential toxicity, natural hepcidin is prohibitively expensive for human application and has unfavorable pharmacologic properties. Here, we report the rational design of hepcidin agonists based on the mutagenesis of hepcidin and the hepcidin-binding region of ferroportin and computer modeling of their docking. We identified specific hydrophobic/aromatic residues required for hepcidin-ferroportin binding and obtained evidence in vitro that a thiol-disulfide interaction between ferroportin C326 and the hepcidin disulfide cage may stabilize binding. Guided by this model, we showed that 7–9 N-terminal amino acids of hepcidin, including a single thiol cysteine, comprised the minimal structure that retained hepcidin activity, as shown by the induction of ferroportin degradation in reporter cells. Further modifications to increase resistance to proteolysis and oral bioavailability yielded minihepcidins that, after parenteral or oral administration to mice, lowered serum iron levels comparably to those after parenteral native hepcidin. Moreover, liver iron concentrations were lower in mice chronically treated with minihepcidins than those in mice treated with solvent alone. Minihepcidins may be useful for the treatment of iron overload disorders.

Download full-text


Available from: Shantanu Sharma,
  • Source
    • "This could potentially compensate for lower potency and produce responses equivalent to or better than NM4. Since palmitoylated analogues have limited water solubility, we employed a phospholipid-based, commercially available drug delivery system, PUREBRIGHT ® SL-220 (NOF America Corp., White Plains, NY) that is suitable for delivery of lipidated peptides [44] [45]. Direct comparison revealed that in single dose experiment(s) NM4 showed significant anorectic activity (Fig. 3A) that was dose-dependent (Fig. 3B). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A small library of truncated/lipid-conjugated neuromedin U (NmU) analogs was synthesized and tested in vitro using an intracellular calcium signaling assay. The selected, most active analogs were then tested in vivo, and showed potent anorexigenic effects in a diet-induced obese (DIO) mouse model. The most promising compound, NM4-C16 was effective in a once-weekly-dose regimen. Collectively, our findings suggest that short, lipidated analogs of NmU are suitable leads for the development of novel anti-obesity therapeutics. Copyright © 2015 Elsevier Masson SAS. All rights reserved.
    European Journal of Medicinal Chemistry 06/2015; 101. DOI:10.1016/j.ejmech.2015.07.020 · 3.45 Impact Factor
    • "From the N to the C terminus, the primary sequence of PR65 was (all L-amino acids): iminodiacetic acid, threonine, histidine, diphenylalanine, β-homo proline , arginine, cysteine, arginine, and β-homo phenylalanine. The Cterminal carboxyamide was derivatized with polyethylene glycol (PEG) linker and palmitic acid groups (Preza et al., 2011; Ramos et al., 2012). Minihepcidins could be useful for the prevention of iron overload , or may be used in combination with phlebotomy or chelation for the treatment of existing iron overload (Fung & Nemeth, 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The maintenance of stable extracellular and intracellular iron concentrations requires the coordinated regulation of iron transport into plasma. Iron is a fundamental cofactor for several enzymes involved in oxidation–reduction reactions. The redox ability of iron can lead to the production of oxygen free radicals, which can damage various cellular components. Therefore, the appropriate regulation of systemic iron homeostasis is decisive in vital processes. Hepcidin has emerged as the central regulatory molecule of systemic iron homeostasis. It is synthesized in hepatocytes and in other cells and released into the circulation. It inhibits the release of iron from enterocytes of the duodenum and from macrophages by binding to the iron exporter protein, ferroportin (FPN). FPN is a transmembrane protein responsible for iron export from cells into the plasma. Hepcidin is internalized with FPN and both are degraded in lysosomes. The hepcidin-FPN axis is the principal regulator of extracellular iron homeostasis in health and disease. Its manipulation via agonists and antagonists is an attractive and novel therapeutic strategy. Hepcidin agonists include compounds that mimic the activity of hepcidin and agents that increase the production of hepcidin by targeting hepcidin-regulatory molecules. The inhibition of hepcidin could be a potentially attractive therapeutic strategy in patients suffering from anaemia or chronic inflammation. In this review, we will summarize the role of hepcidin in iron homeostasis and its contribution to the pathophysiology of inflammation and iron disorders. We will examine emerging new strategies that modulate hepcidin metabolism.
    Pharmacology [?] Therapeutics 09/2014; 146. DOI:10.1016/j.pharmthera.2014.09.004 · 9.72 Impact Factor
  • Source
    • "Several other pharmacological tools now have been developed to target the hepcidin axis [75], including “mini-hepcidins” that down-regulate ferroportin [76], [77], BMP inhibitors that block Smad signaling [78], [79], and agents that perturb Stat signaling [80], [81]. The ferristatins are unique in targeting TfR1 degradation [43], [44]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies have shown that the small molecule iron transport inhibitor ferristatin (NSC30611) acts by down-regulating transferrin receptor-1 (TfR1) via receptor degradation. In this investigation, we show that another small molecule, ferristatin II (NSC8679), acts in a similar manner to degrade the receptor through a nystatin-sensitive lipid raft pathway. Structural domains of the receptor necessary for interactions with the clathrin pathway do not appear to be necessary for ferristatin II induced degradation of TfR1. While TfR1 constitutively traffics through clathrin-mediated endocytosis, with or without ligand, the presence of Tf blocked ferristatin II induced degradation of TfR1. This effect of Tf was lost in a ligand binding receptor mutant G647A TfR1, suggesting that Tf binding to its receptor interferes with the drug's activity. Rats treated with ferristatin II have lower TfR1 in liver. These effects are associated with reduced intestinal (59)Fe uptake, lower serum iron and transferrin saturation, but no change in liver non-heme iron stores. The observed hypoferremia promoted by degradation of TfR1 by ferristatin II appears to be due to induced hepcidin gene expression.
    PLoS ONE 07/2013; 8(7):e70199. DOI:10.1371/journal.pone.0070199 · 3.23 Impact Factor
Show more